Cargando…
Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital
BACKGROUND: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs. METHODS: A nested case...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231613/ https://www.ncbi.nlm.nih.gov/pubmed/24229060 http://dx.doi.org/10.1186/1741-7015-11-238 |
_version_ | 1782344464871718912 |
---|---|
author | Bellis, Jennifer R Kirkham, Jamie J Thiesen, Signe Conroy, Elizabeth J Bracken, Louise E Mannix, Helena L Bird, Kim A Duncan, Jennifer C Peak, Matthew Turner, Mark A Smyth, Rosalind L Nunn, Anthony J Pirmohamed, Munir |
author_facet | Bellis, Jennifer R Kirkham, Jamie J Thiesen, Signe Conroy, Elizabeth J Bracken, Louise E Mannix, Helena L Bird, Kim A Duncan, Jennifer C Peak, Matthew Turner, Mark A Smyth, Rosalind L Nunn, Anthony J Pirmohamed, Munir |
author_sort | Bellis, Jennifer R |
collection | PubMed |
description | BACKGROUND: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs. METHODS: A nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring. RESULTS: A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001). CONCLUSIONS: OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs. |
format | Online Article Text |
id | pubmed-4231613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42316132014-11-15 Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital Bellis, Jennifer R Kirkham, Jamie J Thiesen, Signe Conroy, Elizabeth J Bracken, Louise E Mannix, Helena L Bird, Kim A Duncan, Jennifer C Peak, Matthew Turner, Mark A Smyth, Rosalind L Nunn, Anthony J Pirmohamed, Munir BMC Med Research Article BACKGROUND: Off-label and unlicensed (OLUL) prescribing has been prevalent in pediatric practice. Using data from a prospective cohort study of adverse drug reactions (ADRs) among pediatric inpatients, we aimed to test the hypothesis that OLUL status is a risk factor for ADRs. METHODS: A nested case?control study was conducted within a prospective cohort study. Details of all medicines administered were recorded, including information about OLUL status. The odds ratio for OLUL medicines being implicated in a probable or definite ADR was calculated. A multivariate Cox proportional hazards regression model was fitted to the data to assess the influence that OLUL medicine use had on the hazard of an ADR occurring. RESULTS: A total of 10,699 medicine courses were administered to 1,388 patients. The odds ratio (OR) of an OLUL medicine being implicated in an ADR compared with an authorized medicine was 2.25 (95% confidence interval (CI) 1.95 to 2.59). Medicines licensed in children but given to a child below the minimum age or weight had the greatest odds of being implicated in an ADR (19% of courses in this category were implicated, OR 3.54 (95% CI 2.82 to 4.44). Each additional OLUL medicine given significantly increased the hazard of an ADR (hazard ratio (HR) 1.3 95% CI 1.2 to 1.3, P <0.001). Each additional authorized medicine given also significantly increased the hazard (HR 1.2 95% CI 1.2 to 1.3, P <0.001). CONCLUSIONS: OLUL medicines are more likely to be implicated in an ADR than authorized medicines. The number of medicines administered is a risk factor for ADRs highlighting the need to use the lowest number of medicines, at the lowest dose for the shortest period, with continual vigilance by prescribers, in order to reduce the risk of ADRs. BioMed Central 2013-11-07 /pmc/articles/PMC4231613/ /pubmed/24229060 http://dx.doi.org/10.1186/1741-7015-11-238 Text en Copyright © 2013 Bellis et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bellis, Jennifer R Kirkham, Jamie J Thiesen, Signe Conroy, Elizabeth J Bracken, Louise E Mannix, Helena L Bird, Kim A Duncan, Jennifer C Peak, Matthew Turner, Mark A Smyth, Rosalind L Nunn, Anthony J Pirmohamed, Munir Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
title | Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
title_full | Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
title_fullStr | Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
title_full_unstemmed | Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
title_short | Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
title_sort | adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231613/ https://www.ncbi.nlm.nih.gov/pubmed/24229060 http://dx.doi.org/10.1186/1741-7015-11-238 |
work_keys_str_mv | AT bellisjenniferr adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT kirkhamjamiej adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT thiesensigne adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT conroyelizabethj adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT brackenlouisee adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT mannixhelenal adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT birdkima adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT duncanjenniferc adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT peakmatthew adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT turnermarka adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT smythrosalindl adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT nunnanthonyj adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital AT pirmohamedmunir adversedrugreactionsandofflabelandunlicensedmedicinesinchildrenanestedcasecontrolstudyofinpatientsinapediatrichospital |